{{practice}} has been pre-approved to offer Endolift® in {{city}}.
Following a structured review of aesthetic practices in the Los Angeles metro area, MediPrisma LLC has identified your practice as meeting the full set of criteria required for Endolift® provider status.
This invitation is personalized, time-limited, and non-transferable. It gives your practice direct access to the clinical pack, device evaluation pathway, and provisional position on the {{city}} provider shortlist.
Accepting requests the clinical pack and permission to contact you. Does not commit your practice to purchase.
A new structural treatment tier for {{practice}}, and exclusive provider positioning in {{city}}.
The invitation gives your practice direct access to the evidence pack, device overview, training pathway, and {{city}} shortlist review.
Clinical pack
Protocol, published evidence, safety summaries, and patient-positioning materials.
Device evaluation
LASEmaR® 1500 overview, acquisition pathways, and medical-liaison call.
Training pathway
Provider onboarding, protocol review, and clinical implementation planning.
Market position
Shortlist consideration for the {{city}} provider territory.
The Procedure
Endolift® is a subdermal 1470nm laser procedure delivering selective adipolysis, immediate tissue contraction, and sustained collagen remodeling through a single-use optical fiber inserted beneath the skin surface. No incisions. Local anesthetic only. Outpatient setting.
It addresses tissue layers that no surface-applied or transcutaneous platform can reach – occupying a clinical position between injectable treatment and surgical intervention.
The Commercial Position
Per-session fees in the US market range from $3,000 to $5,500. The procedure does not require a surgical suite, operates under local anesthetic, and uses single-use consumable fibers – yielding a margin profile consistent with premium injectable procedures rather than capital-equipment-heavy treatments.
Finance options through Reliant Capital with credit decisions typically within 2–4 hours. Full commercial modeling available in the Clinical Pack.
Your Exclusivity
Endolift® invitations are issued to one practice per metropolitan area per cycle. Pre-approved status in {{city}} is specific to {{practice}} and cannot be transferred.
Patients in your area searching for Endolift® currently find limited or no certified providers nearby. Acceptance places your practice at the front of this curve before the next review cycle begins.
Selected Endolift® results across face, neck, and body indications.
Representative before and after outcomes, presented in a clean carousel that fits the current brand style. Results vary by patient, indication, practitioner experience, and anatomical site.
Your practice passed our pre-approval review.
Before extending an invitation, our team conducts a structured review of aesthetic practices in each target area. We assess a defined set of criteria before any practice is shortlisted. {{practice}} met the threshold across all of the following.
Verified Clinical Credentials
The lead physician holds active board certification or equivalent clinical qualification in an aesthetic or medical specialty.
Established Patient Base
The practice has a documented patient volume consistent with successful integration of a premium procedure tier.
Positive Patient Reputation
Public review profile reflects consistently high patient satisfaction and clinical outcomes across multiple platforms.
Suitable Treatment Environment
The practice operates a compliant clinical facility appropriate for minor outpatient procedures under local anesthetic.
Aesthetic Procedure Portfolio
The practice already offers injectable, laser, or energy-based treatments, indicating an existing patient population suited to Endolift®.
Geographic Availability
No, or very few, other Endolift®-certified providers are currently operating within your immediate service area.
Pre-approval is reviewer-led, not automated. Each invitation is issued individually and tracked.
Your invitation is open for 30 more days. {{practice}} qualifies on every criterion above.
How Endolift® works - a subdermal laser platform that addresses tissue layers no surface-applied device can reach.
The LASEmaR® 1500 delivers 1470nm laser energy via a single-use optical fiber placed subdermally through a micro-entry point. The procedure addresses three simultaneous tissue targets through one session.
Subdermal Delivery
A micro-optical fiber delivers 1470nm laser energy through a small entry point, with the 1470nm wavelength preferentially absorbed by adipocyte membranes for selective adipolysis.
Immediate Contraction
Thermal effect induces instant tissue contraction and hemostasis – producing the visible initial tightening response within the session itself.
Collagen Stimulation
Thermal energy activates resident fibroblasts in the reticular dermis. Neo-collagenesis and elastin remodeling continue over weeks to months.
Visible Results
Improved laxity, contour, and skin quality. Twelve-month follow-up data confirms maintained dermal thickening and volume reduction over this period.
Why 1470nm Specifically
At 1470nm, laser energy exhibits a water absorption coefficient approximately four times higher than at 980nm and significantly higher than 1064nm. This produces a narrower thermal zone with a steeper absorption gradient – enabling precise subdermal energy delivery without the broader collateral heating profile of shorter near-infrared wavelengths. The result is targeted adipolysis and fibroblast activation with a margin that accommodates safe outpatient delivery under local anesthetic.
LASEmaR® 1500
Engineered for precision. Designed for clinical confidence. The LASEmaR® 1500 is a 1470nm diode laser platform purpose-built for minimally invasive aesthetic procedures.
- Micro-optical fiber delivery for targeted energy
- Real-time tissue interaction with controlled thermal profile
- Ergonomic, compact design for clinical efficiency
- Built-in safety systems and intuitive interface
| Wavelength | 1470 nm |
|---|---|
| Power | Up to 15W |
| Fiber | 200 to 1000 microns |
| Indications | Face, neck, body |
| Downtime | Minimal, 2 to 5 days |
| Clearance | FDA 510(k) K092860 · CE Class IIb · ISO 13485 |
Most non-surgical aesthetic platforms operate from the surface. Endolift® does not.
The treatment gap between injectable procedures and surgical intervention has been underserved by available technology. The table below positions Endolift® relative to the platforms already in your clinic.
| Treatment | Depth of Action | Fat Reduction | Collagen Stimulation | Anesthetic | Downtime |
|---|---|---|---|---|---|
| RF Microneedling | Partial subdermal | Limited | Moderate | Topical | 2–5 days |
| HIFU / Ultrasound | Limited subdermal | No | Moderate | None | Minimal |
| Threadlift | Mechanical subdermal | No | Mild | Local | 3–7 days |
| External Laser | Surface only | No | Surface only | None | Varies |
| Surgical Facelift | Full subdermal | Partial | Incidental | General / IV | 2–4 weeks |
| Endolift® | Targeted subdermal | Yes | Strong - histologically confirmed | Local | 2–5 days |
Endolift® occupies the clinical space between injectable treatment and surgery. It addresses the structural tissue layer that no other non-surgical platform reaches, at outpatient cost and complexity.
The patients you cannot fully serve today.
Within every established aesthetic practice, there is a patient cohort that presents beyond the ceiling of injectables but below the threshold – psychologically or clinically – for surgical referral. These patients are often highly loyal, treatment-experienced, and commercially valuable. They currently leave your clinic without a structural solution.
- The patient between injectable ceiling and surgical threshold
- The post-weight-loss patient with residual pockets and laxity
- The patient who has plateaued on filler and is starting to look over-corrected
- The early surgical candidate not yet ready for rhytidectomy
- The localized fat presentation resistant to conservative measures
- The atrophic acne scarring patient - rolling, boxcar, and icepick subtypes
A premium structural procedure at outpatient operating cost.
The margin profile of Endolift® is determined by three variables: session fee, single-use consumable cost per fiber, and procedure time. The figures below are drawn from current US market data across certified providers.
Typical US market range
Device acquisition, indicative
Following training completion
Does Not Cannibalize
Endolift® serves a patient cohort your existing menu cannot reach. RF, HIFU, and injectable revenue is not displaced – the procedure adds a structural tier above your current ceiling.
Premium Tier Positioning
The procedure's clinical complexity and device-driven delivery support premium price positioning. Comparable market data shows per-session fees above most injectable procedures and energy device treatments.
Patient Retention
Providing a structural solution retains the treatment-ceiling patient within your practice rather than referring them to a surgical competitor – with a rebooking cycle for maintenance sessions.
Commercial figures are indicative. Performance varies by market, pricing strategy, patient throughput, and acquisition pathway. Individual results cannot be guaranteed.
Detailed acquisition options & finance pathways are in the Clinical Pack.
The procedure your patients are already searching for.
Consumer awareness of Endolift® has been driven by international press coverage across the past 24 months. Patient search volume is ahead of provider availability in most US markets.
Google Trends snapshot captured in April 2026, showing elevated U.S. search demand for Endolift® while local certified provider availability remains limited.
Patients searching "Endolift near me" in {{city}} today find limited or no certified options. {{practice}}'s pre-approval places your practice at the front of this curve.
Published clinical evidence includes peer-reviewed RCT, observational, and prospective data.
Randomized Controlled Trial
Bernardini et al. - Lasers in Surgery and Medicine, 2021. 96 subjects.
Prospective RCT evaluating Endolift® for facial and neck rejuvenation. Primary endpoints: tissue laxity and patient satisfaction at 6 months. Results consistent with clinically significant improvement in the treated cohort.
Prospective Observational
Tretti Clementoni et al. - Journal of Cosmetic and Laser Therapy, 2019.
Prospective evaluation of submental and jowl treatment. Histological analysis at 30 days post-procedure confirms new collagen fiber formation and adipocyte disruption consistent with the proposed mechanism of action.
Histological Analysis
Biopsied tissue analysis - multiple independent sites. 1, 3, 6, 12-month timepoints.
Serial biopsy data from treated and control sites. Findings include statistically significant increases in collagen type I density, new elastin deposition, and measurable reduction in adipocyte volume at 12-month follow-up.
Retrospective Cohort
Scuderi et al. - Aesthetic Plastic Surgery, 2022. Multi-center data.
Multi-center retrospective review of 140 patients treated across face, neck, and body indications. Safety profile consistent with outpatient delivery; no reports of serious adverse events attributable to device at 6-month follow-up.
Systematic Review
Independent systematic review of 1470nm subdermal laser technology - published literature to 2023.
The full clinical evidence package – including all cited studies, methodology summaries, and safety data tables – is included in the Endolift® Clinical Pack. Histological evidence of new collagen formation is a consistent finding across independent research groups. All clinical claims on this page defer to published literature; individual patient outcomes cannot be guaranteed.
Histological evidence of neo-collagenesis and elastin deposition is a consistent finding across independently conducted biopsy studies. All claims on this page refer to published data and do not constitute a guarantee of individual outcomes.
What is included with your pre-approved Endolift® provider package.
- LASEmaR® 1500 device - compact desktop unit, fully configured
- Single-use sterile fiber kit - RING (360°) and FLAT (directional) options
- Comprehensive, supervised live clinical training at your practice
- Official Endolift® practitioner certification on completion
- A complete marketing kit, designed to launch fast
- Listing in the public Endolift® practitioner directory
- Endolift® Online Academy - clinical reference video library
- Endolift® Practitioner Community - private peer network
- Endolift® Masters Series - advanced technique training
- Ongoing US-based clinical and commercial support from MediPrisma LLC
Acquisition note: Outright purchase and finance lease options available. Finance through Reliant Capital – credit decisions typically within 2–4 hours. Onboarding from confirmed acquisition to first independent patient treatment: typically 3–6 weeks depending on scheduling.
Why your invitation is time-limited.
MediPrisma LLC issues Endolift® invitations on a rolling review cycle. Each cycle covers a defined geographic area, in this case the greater {{city}} metro, with a fixed number of provider slots. Pre-approval is valid for 30 days from issue. After expiration, the slot is released for the next review cycle. Approval in a later cycle is not guaranteed, because invitations are intentionally limited to preserve premium positioning and avoid oversaturating the market ahead of demand.
- Pre-approval is specific to {{practice}} and cannot be transferred
- One pre-approved invitation per practice per review cycle
- Expired invitations require re-entry to the qualification review
- Future cycles in {{city}} are not guaranteed within any specific timeframe
Your {{city}} window: 30 days remaining.
Accepting the invitation opens a structured evaluation pathway.
Submission is non-binding. Accepting places your practice on our confirmed contact list and triggers the clinical pack delivery. Nothing beyond that is assumed.
Receive the Clinical Pack
Delivered to your email within minutes. Full procedure overview, evidence summaries, device specifications, and commercial modeling.
Discuss Clinical Fit
Our US Medical Liaison contacts you within one business day. Indication selection, workflow integration, and menu positioning.
Review Acquisition Options
If there is genuine interest, purchase and finance pathways through Reliant Capital are walked through in detail. No pressure timeline.
Plan Training & Launch
Onboarding includes supervised training, certification, and launch support. First independent patient treatment typically within 3–6 weeks.
Talk to the team. Review the evidence. Understand the model. Then decide.
Common questions from medical directors.
The pre-approval is reviewer-led and based on the six criteria listed on this page. Our team identifies practices in each target area using publicly available data – review profile, procedure portfolio, facility type, and geographic availability. Not every practice in the area receives an invitation. This invitation was issued to {{practice}} specifically because it met the threshold across all six criteria. It is not a mass-market campaign.
The LASEmaR® 1500 is FDA-cleared under 510(k) reference K092860. It holds CE Mark Class IIb certification and is manufactured under ISO 13485 quality management standards at Eufoton® S.r.l., Trieste, Italy. Device clearance, certification documents, and the current FDA database entry are included in the Clinical Pack.
Training begins with a theory and protocol session covering anatomy, energy delivery parameters, indication selection, and contraindications. This is followed by supervised live clinical sessions – the number varies by prior experience and indication range – with certification issued on confirmation of competence. Training typically takes place at a regional MediPrisma training center or, in some circumstances, on-site at the practice. The full training pathway is outlined in the Clinical Pack.
No. Endolift® serves a patient cohort that existing transcutaneous energy devices cannot reach – specifically those requiring subdermal fat reduction and structural tissue remodeling. RF and HIFU generate thermal energy from the surface, with limited subdermal penetration and no direct adipolysis. Endolift® operates subdermally via optical fiber. The procedures are complementary, not competing. Practices typically find that offering Endolift® creates a premium structural tier that enhances, rather than replaces, their existing energy-device revenue.
Published clinical data and real-world practice report typical downtime of 2–5 days, characterized by swelling and mild bruising at the entry point and treatment area. Patients are generally able to resume light activity within 24–48 hours. Recovery varies by treatment area, energy settings, and individual patient factors. Precise downtime expectations for specific indication combinations are detailed in the Clinical Pack.
Published multi-center retrospective data (Scuderi et al., 2022, n=140) reports no serious adverse events attributable to the device at 6-month follow-up. Expected events – temporary swelling, bruising, and mild discomfort at the entry point – resolved within the standard recovery window across the published literature. The full safety data table and adverse event profile are included in the Clinical Pack. Endolift® is a Class IIb medical device – appropriate clinical training and patient selection are prerequisites to safe delivery.
Device pricing is provided directly during the acquisition conversation, not published on this page. Finance options through Reliant Capital are available for qualifying practices, with credit decisions typically within 2–4 hours. The Clinical Pack includes a commercial modeling summary based on indicative US market session fees and consumable costs, which your team can use to evaluate the acquisition case prior to the acquisition conversation.
This invitation is addressed to the medical director, lead physician, or principal of {{practice}}. If you are not that person, please forward this page link directly to them today – the invitation expires on May 30, 2026 and is held in the name of the practice. The link can be shared internally. If the right person at your practice has not seen this invitation before the expiration date, the slot will be released.
Accept your pre-approved Endolift® invitation.
Submit below to confirm interest. You will receive the Clinical Pack within minutes, a direct call from our US Medical Liaison within one business day, and provisional reservation of {{practice}}’s position on the {{city}} shortlist for 7 days.
For Medical Professionals only · Submission is non-binding · Your information is held by MediPrisma LLC and used solely to coordinate your Endolift® onboarding.
For Medical Professionals Only.
Endolift® is distributed in the United States by MediPrisma LLC. The LASEmaR® 1500 is designed and manufactured by Eufoton® S.r.l., Trieste, Italy. FDA-cleared, 510(k) reference K092860. CE Mark Class IIb. ISO 13485. This page is directed exclusively at licensed medical professionals. Results vary by patient, indication, practitioner experience, and anatomical site. Individual outcomes cannot be guaranteed. All clinical claims on this page defer to published peer-reviewed literature. Endolift®, EndoliftX®, and LASEmaR® are registered trademarks of Eufoton® S.r.l. This invitation is non-transferable and addressed to the named practice only.